Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Debra Griner

Nurse Practitioner, Family Casper, WY Nurse Practitioner

NPI 1861460289 CMS profile 10517083

3632 American Way, Casper, WY 82604

Open in the dashboard

General payments

$9,130

434 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Debra Griner of Casper, WY is reported in the CMS Open Payments database as having received $9,130 across 434 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,169 95
2024 General $1,923 106
2023 General $2,245 104
2022 General $1,608 77
2021 General $1,185 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Debra Griner
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Debra Griner were reported at $2,169. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Debra Griner Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $1,185 $124 $35–$379 $132
2022 $1,608 $141 $44–$430 $149
2023 $2,245 $154 $49–$476 $160
2024 $1,923 $165 $51–$504 $164
2025 $2,169 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novartis Pharmaceuticals Corporation $702 39 payments
  2. Pfizer Inc. $644 44 payments
  3. AstraZeneca Pharmaceuticals LP $623 22 payments
  4. Janssen Biotech, Inc. $582 17 payments
  5. Incyte Corporation $474 21 payments
  6. Merck Sharp & Dohme Corporation $405 21 payments
  7. Seattle Genetics, Inc. $371 14 payments
  8. Amgen Inc. $351 18 payments
  9. AbbVie, Inc. $334 21 payments
  10. Exelixis Inc. $310 2 payments
  11. Other $4,333 215 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $8,162 422 payments
  2. Education $968 12 payments
Products named General payments · program years 2021–2025
  1. KEYTRUDA $405 21 payments
  2. IMFINZI $353 10 payments
  3. KISQALI $321 17 payments
  4. IMBRUVICA $318 17 payments
  5. CABOMETYX $290 1 payment
  6. ORGOVYX Hormone Therapy $284 17 payments
  7. XTANDI $272 17 payments
  8. ORGOVYX Oncology $248 15 payments
  9. EPKINLY $227 12 payments
  10. JEVTANA $226 5 payments
  11. Other $8,369 443 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

687

Median for Nurse Practitioner: 389

Drug cost

$457,120

Median for Nurse Practitioner: $21,885

Branded share of claims

19.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Imbruvica Ibrutinib Brand 26 $360,285
Imatinib Mesylate Generic 31 $34,962
Eliquis Apixaban Brand 34 $32,887
Xarelto Rivaroxaban Brand 20 $19,398
Tamoxifen Citrate Generic 109 $3,189
Anastrozole Generic 84 $1,749
Potassium Chloride Generic 88 $1,182
Valacyclovir Valacyclovir Hcl Brand 11 $902
Acyclovir Generic 38 $565
Gabapentin Generic 25 $334

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 134 billing codes

Paid by Medicare

$2,224,152

Of which drugs: $2,070,669

Medicare patients

642

Average age 75

Services billed

125,162

414 women, 228 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 67%
Arthritis 45%
Cancer 39%
Osteoporosis 34%
Ischemic heart disease 25%
Diabetes 24%
COPD 22%
Chronic kidney disease 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 147 15,120 $311,235
Injection, ferric derisomaltose, 10 mg J1437 Office 22 3,100 $49,688
Injection, ferric carboxymaltose, 1 mg J1439 Office 11 12,750 $10,778
Injection, aprepitant, 1 mg J0185 Office 16 3,900 $5,188
Injection, zoledronic acid, 1 mg J3489 Office 16 80 $353
Injection, palonosetron hcl, 25 mcg J2469 Office 22 440 $340
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 29 814 $74
Injection, diphenhydramine hcl, up to 50 mg J1200 Office 26 46 $30
Injection, potassium chloride, per 2 meq J3480 Office 11 265 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 55 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IMFINZI
  • AstraZeneca Pharmaceuticals LP $88
$88 — —
KISQALI
  • Novartis Pharmaceuticals Corporation $84
$84 — —
ENHERTU
  • Daiichi Sankyo Inc. $56
  • AstraZeneca Pharmaceuticals LP $26
$82 — —
JAKAFI
  • Incyte Corporation $76
$76 — —
ONIVYDE
  • Ipsen Biopharmaceuticals, Inc $63
$63 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 55 with Patron

Records

434 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Wyoming

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record